Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/AnaptysBio, Inc./ SCHEDULE 13G/A

SEC Filing · SCHEDULE 13G/A

AnaptysBio, Inc.

ANABNASDAQEQUITYCurrent

SEC Filing

Filed Aug 14, 2026Accepted Aug 14, 2026, 8:31 AM EDTCIK 1370053Accession 0000919574-26-005200
View company →Permanent SEC source ↗
Share

Company context

Anaptys manages the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning the value of its royalties to shareholders. To learn more, visit www. AnaptysBio.com or follow us on LinkedIn.

Current securities

ANABNASDAQ · EQUITY · Current

Recent company filings

  1. 10-KT filingSep 21, 2026
  2. Financial Statements and ExhibitsSep 21, 2026
  3. Submission of Matters to a Vote of Security HoldersAug 11, 2026
  4. Regulation FD DisclosureJul 30, 2026
  5. ARS filingJun 29, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗